Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2006

01.02.2006 | Original Article

Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL)

verfasst von: Rong Lu, Jing Jia, Leyuan Bao, Zheng Fu, Guoli Li, Song Wang, Zhuo Wang, Mengjue Jin, Wenyuan Gao, Zhi Yao

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose: To investigate the antitumor effects of tyroserleutide (tyrosyl-seryl-leucine, YSL) on human Bel7402 hepatocarcinoma in vitro and in vivo, with preliminary exploration of its antitumor mechanism. Methods: MTT was used to observe the anticarcinogenic effects of YSL on human hepatocarcinoma Bel7402 cells in vitro. The ultrastructure of tumor cells was observed by electron microscopy. Nude mice bearing xenografts of human hepatocarcinoma Bel7402 were given daily i.p. injections of YSL or saline and an admixture of amino acids as controls, after tumor implantation. The inhibition of xenografts was determined by calculating the tumor volume and measuring tumor weight. The effects of YSL on the cell cycle and apoptosis of Bel7402 cells were determined by flow cytometry, and the effects on the ultrastructure of the cells by electron microscopy. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and proliferating-cell nuclear antigen (PCNA) immunohistochemical staining were used to investigate apoptosis in tumor tissue in nude mice. Results: In vitro YSL inhibited the proliferation of human Bel7402 tumor cells and changed their ultrastructure, resulting in the necrosis and apoptosis of the tumor cells. YSL at 80, 160, or 320 μg/kg/d inhibited tumor growth in nude mice by 40.26, 64.17, and 59.19%, respectively, which are significantly lower than the inhibition exerted by saline and an admixture of YSL amino acids (P<0.05). The ultrastructure and cell cycle of human hepatocarcinoma Bel7402 cells were changed by treatment with YSL, with a rate of apoptosis higher than that of the control group. TUNEL and PCNA analysis showed that YSL inhibited the proliferation of tumor cells and induced apoptosis at the level of the cell. Conclusions: YSL significantly inhibited human hepatocarcinoma Bel7402 growth in vitro and in vivo. The growth inhibition of the tumor may involve necrosis and apoptosis of the tumor induced by YSL.
Literatur
1.
Zurück zum Zitat Dwyer JM (1996) Transfer factor in the age of molecular biology: a review. Biotherapy 9:7–11PubMedCrossRef Dwyer JM (1996) Transfer factor in the age of molecular biology: a review. Biotherapy 9:7–11PubMedCrossRef
2.
Zurück zum Zitat Berressem Peter (1991) Application of glycopeptide fractions in the treatment of tumor patients suffering from immunodeficiency. Therapeutikon 5:264–270 Berressem Peter (1991) Application of glycopeptide fractions in the treatment of tumor patients suffering from immunodeficiency. Therapeutikon 5:264–270
3.
Zurück zum Zitat Wang C, Ding W, Zhao M, Lin G, Peng S (2003) Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol 33:189–195CrossRefPubMed Wang C, Ding W, Zhao M, Lin G, Peng S (2003) Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol 33:189–195CrossRefPubMed
4.
Zurück zum Zitat Ding W, Zhang J, Yao Z, Lu R, Wu D, Li G et al (2004) The synthesis, distribution, and anti-hepatic cancer activity of YSL. Bioorg Med Chem 12:4989–4994CrossRefPubMed Ding W, Zhang J, Yao Z, Lu R, Wu D, Li G et al (2004) The synthesis, distribution, and anti-hepatic cancer activity of YSL. Bioorg Med Chem 12:4989–4994CrossRefPubMed
5.
Zurück zum Zitat Li Y, Tang ZY, Wang L, Yao Z, Lu R, Xue Q et al (2004) The inhibitory of tripeptide CMS024 on the metastasis of human hepatocarcinoma in nude mice. J Chin Med 84:675–679 Li Y, Tang ZY, Wang L, Yao Z, Lu R, Xue Q et al (2004) The inhibitory of tripeptide CMS024 on the metastasis of human hepatocarcinoma in nude mice. J Chin Med 84:675–679
6.
Zurück zum Zitat Xu SY, Bian RL, Chen X (2002) Methodology of pharmacological experiment (3rd edn). People’s Health Publishing House pp 1785–1786 Xu SY, Bian RL, Chen X (2002) Methodology of pharmacological experiment (3rd edn). People’s Health Publishing House pp 1785–1786
7.
Zurück zum Zitat Han Y (1997) The research and experiment techniques of anticarcinoma drugs (1st edn). Beijing medical university and China Xiehe medical university united Publishing House p 299 Han Y (1997) The research and experiment techniques of anticarcinoma drugs (1st edn). Beijing medical university and China Xiehe medical university united Publishing House p 299
8.
Zurück zum Zitat Roger JB (1996) Cancer Biology (2nd edn). King Pearson Education Limited:199 Roger JB (1996) Cancer Biology (2nd edn). King Pearson Education Limited:199
9.
Zurück zum Zitat Schwartzman RA, Cidlowski JA (1993) Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocrine Rev 14:133CrossRef Schwartzman RA, Cidlowski JA (1993) Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocrine Rev 14:133CrossRef
10.
Zurück zum Zitat Vermes I, Haanen C (1994) Apoptosis and programmed cell death in health and disease. Adv Clin Chem 31:177PubMed Vermes I, Haanen C (1994) Apoptosis and programmed cell death in health and disease. Adv Clin Chem 31:177PubMed
11.
Zurück zum Zitat Xu KL (1997) The review of the abnormal modulation of apoptosis gene in the occurrence and development of tumor and lung cancer. J Cancer Chin 7:4 Xu KL (1997) The review of the abnormal modulation of apoptosis gene in the occurrence and development of tumor and lung cancer. J Cancer Chin 7:4
12.
Zurück zum Zitat Lowe SW, Lin AW (2000) Apotosis in cancer. Carcinogenesis 21:485–495 Lowe SW, Lin AW (2000) Apotosis in cancer. Carcinogenesis 21:485–495
13.
Zurück zum Zitat Chabner BA (1982) The role of drugs in cancer treatment. In: Chabner B (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 1–14 Chabner BA (1982) The role of drugs in cancer treatment. In: Chabner B (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 1–14
14.
Zurück zum Zitat Chen ruiming, Zhu dehou, Ye xiuzhen (1975) The establishment and character of human hepacarcimoma cell line (BEL-7402) in vitro. Comm Sci 20:434–436 Chen ruiming, Zhu dehou, Ye xiuzhen (1975) The establishment and character of human hepacarcimoma cell line (BEL-7402) in vitro. Comm Sci 20:434–436
15.
Zurück zum Zitat Wright WE, Shay JW (2001) Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev 11:98–103CrossRefPubMed Wright WE, Shay JW (2001) Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev 11:98–103CrossRefPubMed
16.
Zurück zum Zitat Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4:303–313CrossRefPubMed Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4:303–313CrossRefPubMed
17.
Zurück zum Zitat Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239–247PubMed Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239–247PubMed
18.
Zurück zum Zitat Marcel L, Simone K, Barbara S (1998) Differentiation between apoptotic and necrotic cell death by means of the bm cell death detection elisa or annexin V staining. Biochemicano 2 Marcel L, Simone K, Barbara S (1998) Differentiation between apoptotic and necrotic cell death by means of the bm cell death detection elisa or annexin V staining. Biochemicano 2
19.
Zurück zum Zitat Darzynkiewicz Z, Li X, Gong J (1994) Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol 41:15–38PubMedCrossRef Darzynkiewicz Z, Li X, Gong J (1994) Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol 41:15–38PubMedCrossRef
20.
Zurück zum Zitat McDonnell TJ, Meyn RE, Robertson LE (1995) Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 6:53–60CrossRefPubMed McDonnell TJ, Meyn RE, Robertson LE (1995) Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 6:53–60CrossRefPubMed
Metadaten
Titel
Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL)
verfasst von
Rong Lu
Jing Jia
Leyuan Bao
Zheng Fu
Guoli Li
Song Wang
Zhuo Wang
Mengjue Jin
Wenyuan Gao
Zhi Yao
Publikationsdatum
01.02.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-0046-z

Weitere Artikel der Ausgabe 2/2006

Cancer Chemotherapy and Pharmacology 2/2006 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.